Typhoid fever pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 15: Line 15:
*Infective dose 1000 to 1 million
*Infective dose 1000 to 1 million
}}
}}
{{Family tree | | | | |[[Image:Arrow.png|50px]]| | | | | }}
:::[[Image:Arrow.png|50px]]
[[Image:Arrow.png|50px]]
 
{{Familytree|boxstyle=width: 300px; text-align: left;background: #FFF0F5| | | | B01 | | | |B01='''Gastrointestinal Infection'''
{{Familytree|boxstyle=width: 300px; text-align: left;background: #FFF0F5| | | | B01 | | | |B01='''Gastrointestinal Infection'''



Revision as of 21:24, 30 August 2016


Typhoid fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Typhoid fever from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X ray

CT

MRI

Ultrasound

Other Imaging Findings

Other diagnostic tests

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Typhoid fever pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Typhoid fever pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Typhoid fever pathophysiology

CDC on Typhoid fever pathophysiology

Typhoid fever pathophysiology in the news

Blogs on Typhoid fever pathophysiology

Directions to Hospitals Treating Typhoid fever

Risk calculators and risk factors for Typhoid fever pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology


 
 
 
Innoculation
  • Orofecal transmission
  • Infective dose 1000 to 1 million
 
 
 
 
 
 
Gastrointestinal Infection

Stomach

  • Enters stomach
  • High tolerance for acid
  • Survives PH as low as 1.5

Small intestine

  • Adherence to mucosal cells
  • Invade mucosal M cells overlying payers patches
  • Internalisation in M cells
  • Translocation to underlying lymphoid tissue and draining lymph nodes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Systemic spread
  • Dissemination of S.typhi to reticuloendothelial system
  • Spreads via lymph and blood
  • Replication within reticuloendothelial system
  • Evades immune system
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic carrier state
  • Resides and multiplies in gall bladder
  • Excretion in urine and stool
 
 
 

Heterozygous advantage

It is thought that cystic fibrosis may have risen to its present levels (1 in 1600 in UK) due to the heterozygous advantage that it confers against typhoid fever. The CFTR protein is present in both the lungs and the intestinal epithelium, and the mutant cystic fibrosis form of the CFTR protein prevents entry of the typhoid bacterium into the body through the intestinal epithelium.

References

Template:WH

Template:WS